- Home
- ACR vs GNLX Comparison
ACR vs GNLX Comparison
Compare ACR & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACR
- GNLX
- Stock Information
- Founded
- ACR 2005
- GNLX 2001
- Country
- ACR United States
- GNLX United States
- Employees
- ACR N/A
- GNLX N/A
- Industry
- ACR Real Estate Investment Trusts
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ACR Real Estate
- GNLX Health Care
- Exchange
- ACR Nasdaq
- GNLX Nasdaq
- Market Cap
- ACR 154.8M
- GNLX 128.0M
- IPO Year
- ACR N/A
- GNLX 2023
- Fundamental
- Price
- ACR $20.37
- GNLX $5.36
- Analyst Decision
- ACR Buy
- GNLX Strong Buy
- Analyst Count
- ACR 2
- GNLX 4
- Target Price
- ACR $23.50
- GNLX $17.75
- AVG Volume (30 Days)
- ACR 19.2K
- GNLX 138.9K
- Earning Date
- ACR 10-29-2025
- GNLX 11-13-2025
- Dividend Yield
- ACR N/A
- GNLX N/A
- EPS Growth
- ACR N/A
- GNLX N/A
- EPS
- ACR 0.04
- GNLX N/A
- Revenue
- ACR $86,599,000.00
- GNLX N/A
- Revenue This Year
- ACR $7.03
- GNLX N/A
- Revenue Next Year
- ACR $3.26
- GNLX N/A
- P/E Ratio
- ACR $488.32
- GNLX N/A
- Revenue Growth
- ACR 12.74
- GNLX N/A
- 52 Week Low
- ACR $14.87
- GNLX $1.99
- 52 Week High
- ACR $23.81
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- ACR 43.27
- GNLX 67.75
- Support Level
- ACR $20.21
- GNLX $4.17
- Resistance Level
- ACR $20.96
- GNLX $5.72
- Average True Range (ATR)
- ACR 0.43
- GNLX 0.38
- MACD
- ACR -0.06
- GNLX 0.06
- Stochastic Oscillator
- ACR 14.16
- GNLX 76.92
About ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.